Patents Assigned to Heron Therapeutics, Inc.
-
Patent number: 11878074Abstract: Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.Type: GrantFiled: February 19, 2021Date of Patent: January 23, 2024Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Han Han
-
Patent number: 11844837Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an organic acid excipient, and a basic drug are described, along with related methods.Type: GrantFiled: March 22, 2021Date of Patent: December 19, 2023Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Lee Ann Lynn Girotti
-
Patent number: 11744800Abstract: Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.Type: GrantFiled: November 2, 2022Date of Patent: September 5, 2023Assignee: HERON THERAPEUTICS, INC.Inventors: Thomas B. Ottoboni, Han Han
-
Patent number: 11413350Abstract: Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural).Type: GrantFiled: December 21, 2020Date of Patent: August 16, 2022Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Lee Ann Lynn Girotti
-
Patent number: 11253504Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.Type: GrantFiled: July 17, 2019Date of Patent: February 22, 2022Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Lee Ann Lynn Girotti
-
Patent number: 11173118Abstract: Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.Type: GrantFiled: March 16, 2020Date of Patent: November 16, 2021Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Han Han
-
Patent number: 11083797Abstract: Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural).Type: GrantFiled: September 12, 2017Date of Patent: August 10, 2021Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Lee Ann Lynn Girotti
-
Patent number: 11083730Abstract: Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural).Type: GrantFiled: October 21, 2016Date of Patent: August 10, 2021Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Lee Ann Lynn Girotti
-
Patent number: 10980886Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an organic acid excipient, and a basic drug are described, along with related methods.Type: GrantFiled: April 20, 2015Date of Patent: April 20, 2021Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Lee Ann Lynn Girotti
-
Patent number: 10953018Abstract: Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.Type: GrantFiled: October 30, 2019Date of Patent: March 23, 2021Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Han Han
-
Patent number: 10898575Abstract: Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural).Type: GrantFiled: June 13, 2017Date of Patent: January 26, 2021Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Lee Ann Lynn Girotti
-
Patent number: 10632199Abstract: Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural).Type: GrantFiled: August 21, 2018Date of Patent: April 28, 2020Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Lee Ann Lynn Girotti
-
Patent number: 10624850Abstract: Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.Type: GrantFiled: April 27, 2018Date of Patent: April 21, 2020Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Han Han
-
Patent number: 10500208Abstract: Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.Type: GrantFiled: January 5, 2017Date of Patent: December 10, 2019Assignee: HERON THERAPEUTICS, INC.Inventors: Thomas B. Ottoboni, Han Han
-
Patent number: 10398686Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.Type: GrantFiled: March 13, 2017Date of Patent: September 3, 2019Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Lee Ann Lynn Girotti
-
Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
Patent number: 10357570Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.Type: GrantFiled: February 14, 2018Date of Patent: July 23, 2019Assignee: Heron Therapeutics, Inc.Inventors: Steven Y. Ng, Hui-Rong Shen, Jorge Heller -
Patent number: 10213510Abstract: Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural).Type: GrantFiled: April 20, 2015Date of Patent: February 26, 2019Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Lee Ann Lynn Girotti
-
Patent number: 10098957Abstract: Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural).Type: GrantFiled: July 7, 2017Date of Patent: October 16, 2018Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Lee Ann Lynn Girotti
-
Patent number: 9974793Abstract: Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.Type: GrantFiled: September 14, 2017Date of Patent: May 22, 2018Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Han Han
-
Patent number: 9974794Abstract: Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.Type: GrantFiled: September 14, 2017Date of Patent: May 22, 2018Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Han Han